NCT02252263 2017-11-01A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaBristol-Myers SquibbPhase 1 Completed44 enrolled